Ge Long Hui·2025-11-06 11:27Core Insights - The core viewpoint of the article highlights the significant revenue growth and improved profitability of BeiGene in Q3 2025, driven primarily by the sales increase of its product, Brukinsa, in the US and Europe [1] Financial Performance - Total revenue for Q3 2025 reached $1.4 billion, up from $1 billion in the same period last year, representing a 40% year-over-year increase [1] - GAAP gross margin as a percentage of global product revenue was 85.9%, compared to 82.8% in the previous year, indicating an improvement in gross margin [1] - Adjusted gross margin (excluding depreciation and amortization) for Q3 2025 increased to 86.3%, up from 84.9% year-over-year [1] - GAAP net profit for Q3 2025 was $125 million, an increase of $246 million compared to a loss in the same period last year, attributed to revenue growth and operational leverage improvement [1] - Basic and diluted earnings per share were $0.09 and $0.08, respectively, while basic and diluted earnings per ADS were $1.13 and $1.09; this contrasts with a basic loss per share of $0.09 and a basic loss per ADS of $1.15 in the same quarter last year [1]